Bâtiment Adénine

60 Avenue Rockefeller

69008 Lyon France


November 7, 2017

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn:   J. Nolan McWilliams
     Donald E. Field
     Aamira Chaudhry
     Jean Yu


Re: ERYTECH Pharma S.A.
     Registration Statement on Form F-1
     File No. 333-220867


     Acceleration Request

Requested Date:     Thursday, November 9, 2017

Requested Time:    11:30 A.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 to become effective on November 9, 2017, at 11:30 a.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Brian Leaf and Courtney Thorne of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053, or in his absence, Courtney Thorne at (617) 937-2318. Thank you for your assistance with this matter.

[Signature Page Follows]

By:   /s/ Gil Beyen
  Name: Gil Beyen
  Title: Chief Executive Officer


cc:   Eric Soyer, ERYTECH Pharma S.A.
  Marc A. Recht, Cooley LLP
  Divakar Gupta, Cooley LLP
  Brian F. Leaf, Cooley LLP
  Courtney T. Thorne, Cooley LLP